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Diabetic sensorimotor polyneuropathy (DSPN) affects around one third of people with 
diabetes and accounts for considerable morbidity, increased risk of mortality, reduced quality 
of life, and increased health care costs resulting particularly from neuropathic pain and foot 
ulcers. Painful DSPN is encountered in 13-26% of diabetes patients, while up to 50% of 
patients with DSPN may be asymptomatic. Unfortunately, DSPN still remains inadequately 
diagnosed and treated. Herein we provide international expert consensus recommendations 
and algorithms for screening, diagnosis, and treatment of DSPN in clinical practice derived 
from a Delphi process. Typical neuropathic symptoms include pain, paresthesias, and 
numbness particularly in the feet and calves. Clinical diagnosis of DSPN is based on 
neuropathic symptoms and signs (deficits). Management of DSPN includes three 
cornerstones: 1.) lifestyle modification, optimal diabetes treatment aimed at near-
normoglycemia, and multifactorial cardiovascular risk intervention, 2.) pathogenetically 
oriented pharmacotherapy (e.g. α-lipoic acid and benfotiamine), and 3.) symptomatic 
treatment of neuropathic pain including analgesic pharmacotherapy (antidepressants, 
anticonvulsants, opioids, capsaicin 8% patch and combinations, if required) and non-
pharmacological options. Considering the individual risk profile, pain management should not 
only aim at pain relief, but also allow for improvement in quality of sleep, functionality, and 
general quality of life. 




Diabetic neuropathy represents a condition that develops in the context of diabetes and 
cannot be attributed to other causes of peripheral neuropathy1–3. It manifests in the somatic 
and/or autonomic components of the peripheral nervous system. Diabetic sensorimotor 
polyneuropathy (DSPN) is the commonest form affecting approximately one third of people 
with diabetes, while its yearly incidence amounts to approximately 2%4. DSPN has been 
defined as a symmetrical, length-dependent sensorimotor polyneuropathy attributable to 
metabolic and microvessel alterations as a result of chronic hyperglycemia exposure 
(diabetes) and cardiovascular risk covariates5. A simpler DSPN definition for clinical practice 
is the presence of symptoms and/or signs of peripheral nerve dysfunction in people with 
diabetes after the exclusion of other causes2,3. Chronic peripheral neuropathic pain has been 
defined as persistent or recurrent pain lasting ≥3 months caused by a lesion or disease of the 
peripheral somatosensory nervous system6. Neuropathic pain due to diabetes has been defined 
as pain arising as a direct consequence of abnormalities in the somatosensory system in 
people with diabetes after exclusion of other causes7. Chronic painful DSPN is encountered in 
up to one fourth of people with diabetes4. Measures of DSPN have been identified as 
predictors of all-cause mortality and future neuropathic foot ulcerations as well as 
cardiovascular morbidity and mortality8–10. In the DIAD study, both sensory deficits and 
neuropathic pain were independent predictors of cardiac death or nonfatal myocardial 
infarction11. A community-based study from the UK, showed that reduced pressure sensation 
to a 10 g monofilament predicted cardiovascular morbidity12. In the ACCORD trial, a history 
of DSPN was the most important predictor for increased mortality in type 2 diabetes 
individuals receiving highly intensive diabetes therapy aimed at HbA1c <6.0%13. A 
retrospective cohort study showed an increased risk of vascular events and mortality in type 2 
diabetes patients with painful compared to those with non-painful DSPN14 and in an 
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epidemiological survey peripheral neuropathy was found to be common and independently 
associated with mortality in the U.S. population both with and without diabetes.15 
Despite its major impact on morbidity and mortality, DSPN remains an 
underestimated condition by physicians and patients alike. In a German population-based 
survey, 77% of the cases with DSPN were unaware of having the disorder, defined as 
answering "no" to the question "Has a physician ever told you that you are suffering from 
nerve damage, neuropathy, polyneuropathy, or diabetic foot?". Approximately one quarter of 
the subjects with known diabetes had never undergone a foot examination16. In a German 
educational initiative, painful and painless DSPN were previously undiagnosed in 57 and 82% 
of the participants with type 2 diabetes, respectively17. Likewise, in cross-sectional studies in 
Qatar, 80% of type 2 diabetes patients with DSPN reported that they had previously not been 
diagnosed with or treated for this condition18,19. Underdiagnosis and hence underestimation of 
DSPN was also frequent in South-East Asia, possibly due to a lack of consensus on screening 
and diagnostic procedures20. Indeed, it has recently been reasoned that the challenge in most 
countries in this region is that even simple diagnostic tools such as the tuning fork are only 
available in a specialist setting20. Among U.S. physicians using a 10g monofilament, only 31 
and 66% were able to correctly identify mild/moderate and severe DSPN, respectively21. 
A population-based survey from Germany revealed that only 38% of patients with 
painful DSPN (i.e. with average pain level during the past 4 weeks ≥4 on the numeric pain 
rating scale with 0 indicating no pain and 10 indicating worst pain imaginable) received 
medical treatment which comprised predominantly nonsteroidal anti‐inflammatory drugs for 
which efficacy has not been demonstrated in neuropathic pain conditions22. Underdiagnosis 
and under-/mistreatment of DSPN in clinical practice may be related to a poor acceptance of 
guidelines. A survey among German family practitioners indicated that only 51% were clearly 
positive about guidelines and considered them to provide benefits for patient care. 
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Implementation of clinical guidelines is often perceived as complicated and/or restricting the 
freedom of action for physicians23.
The aim of the present report originating from an International Consensus 
Conference on diagnosis and treatment of diabetic sensorimotor polyneuropathy in clinical 
practice which took place virtually on 11th and 12th of November 2020 on the occasion of the 
World Diabetes Day is to provide clear, condensed, comprehensive and practical 
recommendations and algorithms for the screening, diagnosis and treatment of DSPN in 
clinical practice. 
Consensus finding process
A panel of 15 experts comprising 14 diabetologists and 1 neurologist was selected for 
their contributions and specific expertise in the field of diabetic neuropathy including the 
chair (DZ) and three co-chairs (AJMB, PK, ST). More specifically, the participants were 
selected (1) to represent different geographical regions in the EU, UK, Eastern Europe, 
Russia, Middle East, Asia, and United States, (2) based on their position as key opinion 
leaders and chair functions in national and international medical associations, and (3) given 
their previous contributions to international consensus panels. Around half of the participants 
had contributed to the Toronto Consensus Panel on Diabetic Neuropathy (AJMB, RF, PK, ST, 
VS, TV, DZ), while three participants coauthored the Position Statement of the American 
Diabetes Association (AJMB, RF, DZ). The final list of invited experts was aligned among 
the chairmen before the participants were officially invited.
During the consensus finding process, experts shared their personal clinical experience 
and routine in diagnosing and treating DSPN and examined the recent literature and current 
guidelines to provide consensus recommendations and define algorithms for screening, 
diagnosis and treatment of DSPN that are relevant specifically for clinical practice. The aim 
was to derive consensus recommendations from published data, where available, using a 
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hierarchical approach considering evidence from systematic reviews, meta-analyses, and 
single RCTs and to utilize the participating experts’ own clinical experience where evidence 
from clinical trials is lacking. To reach a consensus, the Delphi method was applied which is a 
structured communication technique where a panel of experts answers questionnaires in ≥2 
rounds24. The number of voting rounds was not prespecified as the intention was to reach a 
consensus on each topic.
The first Delphi round was conducted via SurveyMonkey® before the conference 
comprising qualitative open-ended as well as „tick-box style“ questions (see supplement 1) 
which were developed and aligned among the chairmen before the link was provided to all 
participants. The aim of the survey was to gather information about invited experts’ clinical 
practice and derive drafts for consensus recommendations and algorithms. The drafts were 
then discussed among and adjusted by the experts during the conference which was organized 
by Wörwag Pharma according to the instructions by the chairmen. The second Delphi round 
was also conducted via SurveyMonkey® directly after the conference and included a voting on 
the finetuned statements and algorithms. A 9-point scale with the following numeric and 
descriptive anchors was used to measure agreement: strongly disagree (1), disagree (3), 
neutral (5), agree (7), and strongly agree (9). Ratings of ≤6 were considered as 
“disagreement” and ratings of ≥7 were considered as “agreement”. A consensus was defined a 
priori based on ≥75% of participants agreeing with the statement/algorithm. This approach is 
based on the results of a systematic review by Diamond et al. which reported a median 
threshold for finding a consensus at 75% (range: 50-97%) in Delphi studies24. For each 
statement and algorithm, the level of agreement is presented as the percentage vote of 15 
experts.
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Implementation of guidelines into clinical practice
In general, the main reasons for introducing clinical practice guidelines are to improve 
the quality of medical care and reduce health care disparities25. Guidelines for the screening, 
diagnosis and management of DSPN are of particular interest for both general practitioners 
and specialists, due to the high prevalence of the condition, its socioeconomic and health 
impact, the interdisciplinary nature, the need to weigh the potential risks against the proven 
benefits of a treatment for individual patients, and to make the best use of available 
resources26. Existing guidelines focusing on painful DSPN or neuropathic pain in general 
show inconsistencies as to their recommendations of pharmacotherapies as 1st, 2nd and 3rd line 
treatments2,27–35 (Table 1), which may lower their credibility and create confusion26. The same 
applies to systematic reviews which are frequently inconclusive36. Conclusiveness of evidence 
was higher in systematic reviews which included more participants and randomized controlled 
trials (RCTs), searched more databases, conducted meta-analysis, and examined the quality of 
evidence37.
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Table 1. Recent guidelines for pharmacotherapy of painful diabetic sensorimotor 
polyneuropathy (DSPN) and neuropathic pain in general.



























antidepressants 1 1 2 2 1 1 1 NC 1 1
Duloxetine 1 1 2 2 1 1 1 1 1 1
Venlafaxine 1 NC 2 2 NC 1 1 NR NR 1
Gabapentin 1 1 2 2 1 1 1 1 1 1
Pregabalin 1 1 1 1 1 1  2
$ 1 1 1
Sodium channel 
blockers NC NC NC  2
+ NC NR NR NR NC NR
Tramadol 3 2 2 3 1 2  2
§ NR 2 2/3
Opioids
 3
# 2 2 3 2  3** 3 NR 3 2/3
Capsaicin 8% 
patch NC NC 2 NC 1 2  2
§ NR NC NC
Lidocaine 5% 
patch NC NC NC NC NC 2   1*** NC NR NC
α-Lipoic acid NR 1*/2* NC NC 1 NC NC NC NC NC
Footnotes/Abbreviations: 1 = 1st line; 2 = 2nd line; 3 = 3rd line; NR = not recommended; 
NC = not considered; *intravenously, +valproate, #oxycodone not recommended, **tapentadol 
inconclusive, §weak recommendation, &non-specialist settings, ***focal pain; ADA: 
American Diabetes Association, IDF: International Diabetes Federation, AAN: American 
Academy of Neurology, DDG: German Diabetes Association, NeuPSIG: Neuropathic Pain 
Special Interest Group of the International Association for the Study of Pain (IASP), NICE: 
National Institute for Health and Care Excellence, JSPC: Japanese Society of Pain Clinicians, 
EFNS: European Association of Neurological Societies
For various pain conditions including painful DSPN, treatment adherence to published 
pain management guidelines was associated with lower proportions of hospitalizations, 
emergency department visits, and lower health care costs38. In the population-based 
Australian Diabetes, Obesity, and Lifestyle Study (AusDiab), 77% of participants with 
diabetes reported an eye examination within the previous 2 years, whereas only 50% reported 
that their feet were examined by a health care professional in the previous year39. Visiting a 
diabetes nurse in the past 12 months was an independent predictor of a foot examination. A 
single education session about foot examination for nurses resulted in an increase in the 
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number of foot examinations by nurses in people with diabetes40. A practical approach to 
increase the frequency of routine foot examinations in patients with diabetes may be the 
incorporation into eye screening appointments. Such “one-stop” annual diabetes 
microvascular screening program has been shown to be feasible and well received by patients 
and staff alike41–43. A systematic review and meta-analysis of 14 studies revealed that 
different health education programs may help to increase foot self-care scores and reduce foot 
problems in people with diabetes44. On the other hand, the reported use of practice guidelines 
may not necessarily exert a measurable effect towards the intended reduction of health care 
disparities in patients with DSPN, but rather precipitate more clinical actions potentially 
contributing to increased cost of medical care as an unintended consequence 25. Thus, further 
research is needed to better understand the unintended consequences of implementing clinical 
practice guidelines.
The consensus recommendations for the implementation of guidelines into clinical 
practice are given in Table 2.
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Table 2: Consensus recommendations for the implementation of guidelines for diabetic 
sensorimotor polyneuropathy (DSPN) into clinical practice.




1.1 Guidelines should be clearer on diagnostic procedures, adequate 
treatment choices, dosing, and follow-up to encourage adoption into 
clinical practice.
1.2 To ensure implementation of screening procedures even in the 
absence of neuropathic symptoms, risk assessment for 
cardiovascular and other risk factors as well as diagnosis and 
adequate treatment of DSPN into clinical practice, it is necessary to 
increase awareness and improve education about the disease among 
patients emphasizing their active role, health care practitioners, 
physicians, and relevant stake holders.
1.3 For time efficient routines in clinical practice, DSPN screening 
may be performed by trained staff such as nurses, diabetes 
educators or podiatrists and may be incorporated into e.g. eye 
screening or other routine procedures.
1.4 A risk-based approach including screening for micro- and 










Overall agreement 100 %, Consensus endorsed
Clinical characteristics of DSPN
DSPN usually manifests as a length-dependent distal-symmetrical, sensorimotor 
polyneuropathy. The most important underlying factors include age, height, obesity, 
hypertension, smoking, poor glycemic control, diabetes duration, hypoinsulinemia, and an 
adverse lipid profile5. DSPN is commonly but not invariably associated with autonomic 
involvement2, may commence insidiously, and if intervention is not successful, it becomes 
progressive and chronic2. Lower-limb long axons appear more amenable to injury2 and 
therefore DSPN clinically usually develops first in the feet. Subsequently, it progresses 
proximally and may also include the upper limbs. This corresponds to a “dying-back” type of 
axonal degeneration and patients typically present with a so-called “stocking-glove” like 
distribution of neuronal dysfunction45.
Sensory nerve fiber involvement causes “positive“ symptoms46 such as pain, 














hypoesthesia including different sensory modalities relating to small (temperature, pain) and 
large fiber function (touch, pressure, vibration, position) and ataxic gait. However, this 
differentiation may be difficult for a symptom like “numbness” which can be classified as 
negative if the patient means a deficit of feeling without spontaneous symptoms or as positive 
if an asleep-numbness “like a hand that has gone asleep” is meant46. Remarkably, up to 50% 
of affected subjects do not report symptoms2,3. Conversely, up to one fourth of people with 
diabetes develop painful DSPN4.
Screening and diagnosis of DSPN
The basic neurological assessment comprises the general medical and neurological 
history, inspection of the feet, and neurological examination using simple semi-quantitative 
bedside instruments2.
Patient history and assessment of neuropathic symptoms and signs
Neuropathic symptoms include pain, characteristically described as burning, painful 
cold, lancinating, tingling, stabbing or shooting (electric shock–like), as well as non-painful 
neuropathic symptoms like paresthesias (tingling, prickling or ant-like sensations), 
dysesthesias (unpleasant abnormal sensation whether spontaneous or evoked), sensory ataxia 
(ataxic gait) or numbness (often described as “wrapped in wool” or like “walking on thick 
socks”)2. Neuropathic pain may be accompanied by hyperalgesia (exaggerated response to 
painful stimuli) and allodynia (pain triggered by normally non-painful stimuli such as the 
contact of socks, shoes, or bedclothes). Neuropathic pain typically worsens at night and may 
interfere with daily activities and reduce the quality of life and sleep2. In addition to simple 
orientating questions, the “Douleur Neuropathique en 4 Questions” (DN4-Interview) may 
serve as a useful tool to screen for neuropathic pain in diabetes and may constitute a 
component in the assessment of painful DSPN in clinical practice26,47,48.
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Neuropathic symptoms may reflect different pathophysiology rather than signs, e.g. 
pain or paraesthesias may be related to the degree of compensatory regeneration rather than to 
the degree of nerve fiber damage. Moreover, symptoms may have a heterogeneous long-term 
course with progression and regression to a similar extent49. Screening tools for neuropathic 
pain may offer guidance for further diagnostic evaluation and pain management but do not 
replace clinical judgment.50. The intensity (severity) of neuropathic pain and its course can be 
assessed using an 11-point numeric rating scale (Likert scale) or a visual analogue scale.
Accumulating evidence indicates that the risk of polyneuropathy is increased in 
prediabetes51. In the general population of Augsburg, Southern Germany, the prevalence of 
polyneuropathy was 28% among subjects with known diabetes, 13% among those with 
impaired glucose tolerance (IGT) and 11% among those with impaired fasting glucose (IFG), 
while it was 7% among those with normal glucose tolerance (NGT)52. The corresponding 
prevalence rates of painful polyneuropathy were 13, 9, 4, and 1%53. Thus, screening of 
patients with prediabetes reporting symptoms of DSPN should be considered in clinical 
practice2. 
Small and large nerve fiber damage most frequently coexist in DSPN. Conclusive 
evidence from prospective studies for the postulated progression from early involvement of 
small fibers (inducing pain and/or dysesthesias as first symptoms) to later large-fiber 
dysfunction is missing45,49,54. In contrast, there is evidence in patients recently diagnosed with 
type 2 diabetes suggesting that parallel damage to small and large nerve fibers occurs early in 
the course of diabetes55. Hence, testing both small and large nerve fiber function with 
appropriate bedside tests is equally important.
The clinical examination of DSPN includes the use of semi-quantitative bedside 
instruments45. In clinical practice, assessment of large sensory nerve fiber function mainly 
comprises the measurement of vibration sensation (Rydel-Seiffer tuning fork or an alternative 
vibrating instrument), position sense (proprioception), and touch/pressure perception (e.g. 
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with 10g monofilament or alternatively the Ipswich touch test)2,45,56–58. Since vibration 
sensation declines physiologically with age, it is important to consider age-dependent 
normative values (lower limits for normal sensation using the Rydel-Seiffer tuning fork on the 
dorsal aspect of the hallux are 5/8 for age ≤39, 4.5/8 for age 40-59, 4/8 for age 60-74, 3.5/8 
for age ≥75 years)56. When an automated device such as the Biothesiometer, 
Neurothesiometer, Maxivibrometer, Vibrameter, Vibratron or CASE IV System is used to 
quantitatively measure vibration perception threshold59, age-related reference values provided 
by the manufacturer can be applied. If the monofilament test is applied to the dorsum of the 
big toe, it identifies DSPN. If applied to the sole of the foot, it may also be used to identify 
patients with high ulceration risk2,60. Small nerve fiber function can be assessed in clinical 
practice primarily by testing pain/sharp sensation (pinprick) and temperature 
discrimination2,45,61,62. Tools for assessment of autonomic small nerve fiber function such as 
the Neuropad® indicator test to determine cutaneous sweat production63 or Sudoscan® to 
measure electrochemical skin conductance64 may be used, but these devices were applied by 
the panel too infrequently in clinical practice to allow for a representative statement (see 
supplement 2).
Differential diagnosis
The following findings should alert the physician to consider causes for DSPN other 
than diabetes and trigger referral for a detailed neurological work-up: 1) predominant motor 
rather than sensory deficits, 2) pronounced asymmetry of the neurological deficits, 3) rapid 
development or progression of symptoms or deficits 4) mononeuropathy and cranial nerve 
involvement, 5) progression of the neuropathy despite optimizing glycemic control, 6) onset 
of symptoms and deficits in the upper limbs, 7) family history of non-diabetic neuropathy, 8) 
neurological findings exceeding those typical for DSPN, and 9.) diagnosis of DSPN cannot be 
ascertained by clinical examination with the aforementioned semi-quantitative bedside tests63. 
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The most important differential diagnoses from the general medicine perspective 
include neuropathies caused by alcohol abuse, uremia, hypothyroidism, monoclonal 
gammopathy, vitamin B12 deficiency, paraproteinemias, peripheral arterial disease, cancer, 
inflammatory and infectious diseases, and neurotoxic drugs. Differential diagnosis of DSPN 
should also consider that the causes may vary between different countries as well as urban and 
rural areas20. A meta-analysis found that diabetes patients treated with metformin had an 
increased risk of vitamin B12 deficiency showing dose- and duration-dependent reductions of 
serum vitamin B12 concentrations65. Annual assessment of the vitamin B12 status in people 
with diabetes treated with metformin was suggested65.
The consensus recommendations for screening, clinical diagnosis, and differential 
diagnosis of DSPN are listed in Table 3.
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Table 3: Consensus recommendations for screening, clinical diagnosis, and differential 
diagnosis of DSPN.





2.1 Patient history should encompass neuropathic pain 
characteristics, assessment of pain severity and interference with 
daily activities and sleep.
2.2 For screening or identification of neuropathic pain 
characteristics, appropriate questionnaires such as DN4 may be 
used.
2.3Patient history should encompass non-painful symptoms (e.g. 
paresthesias, numbness, sensory distortion).
2.4 For clinical diagnosis of DSPN in practice, validated scores 
for neuropathic symptoms (e.g. NSS) and signs (e.g. NDS, 










Overall agreement 100%, Consensus endorsed
Clinical diagnosis
3.1 Bilateral impairment of vibration sensation with tuning fork 
(large fiber) and/or pinprick test (small fiber) may be appropriate 
as minimal criteria for diagnosis of DSPN in clinical practice.
3.2 The presence of neuropathic pain and signs of DSPN in the 
same distribution is suggestive of painful DSPN.
3.3 Neuropathic pain in a plausible neuroanatomical distribution, 
i.e. distal symmetrical, may occur in the absence of a clinically 
evident DSPN.
3.4 A single abnormal screening test bilaterally suggests the 











Overall agreement 100%, Consensus endorsed
Differential diagnosis
4.1 Consider other causes of polyneuropathy, e.g. drug-induced, 
by history.
4.2 Assessment of vitamin B12, serum protein electrophoresis, 
eGFR, TSH, blood count, magnesium and liver enzymes may be 
advisable.
4.3 In addition, assessment of vitamin D status may be advisable.










Overall agreement 93%, Consensus endorsed 
Footnotes/abbreviations: DSPN: diabetic sensorimotor polyneuropathy; DN4: “Douleur 
Neuropathique en 4 Questions”; NSS: Neuropathy Symptom Score; NDS: Neuropathy 
Disability Score; MNSI-E: Michigan Neuropathy Screening Instrument Examination part; 
eGFR: estimated glomerular filtration rate; TSH: Thyroid-stimulating hormone. 
The consensus recommendations for the individual modalities of sensory examination are 
shown in Table 4. Notably, clear evidence and detailed guidance on how to perform the semi-






































Table 4: Consensus recommendations for sensory examination in diabetic sensorimotor 
polyneuropathy (DSPN).





5.1 Vibration sensation may be tested using a tuning fork.
5.2 The dorsal big toe (interphalangeal joint) constitutes the primary 
examination site.
5.3 When using a Rydel-Seiffer tuning fork, age-dependent thresholds 
according to Martina et al. 1998 are available56.
5.4 For automated devices, thresholds provided by the manufacturer are 
applicable.
5.5 If a calibrated tuning fork is not available, a simpler vibrating tool or 
tuning fork using an “on-off” or double-dummy technique with mock-










Overall agreement 100%, Consensus endorsed
Pressure/touch sensation
6.1 Pressure/touch sensation may be tested using a 10g monofilament or 
cotton wool/Q-tip or tissue.
6.2 This test can identify DSPN and feet at high risk of ulceration depending 
on the application site.
6.3 For identification of DSPN:
- The dorsum of the big toe constitutes the primary examination site60.
- Pressure/touch sensation is considered impaired if in total ≥5 out of 8 
contacts (4 per foot) are not sensed by the patient60.
6.4 In resource-limited situations the Ipswich touch test may be an 
alternative57,58.
6.5 Allodynia can be assessed with a cotton wool/Q-tip, soft brush or tissue 










Overall agreement 100%, Consensus endorsed
Pain/sharp sensation
7.1 Pain or sharp sensation may be tested using a NeurotipTM/Neuropen®, 
pinprick or similar.
7.2 The dorsal side of the big toe and foot constitutes the primary 
examination site.
7.3 Pain sensation is considered impaired if ≥2 out of 3 contacts per foot are 
not perceived as “painful” by the patient.










Overall agreement 93%, Consensus endorsed
Temperature sensation
8.1 Temperature sensation may be tested using a Tiptherm®, cold tuning fork 
or similar.
8.2 The dorsal side of the foot and big toe constitute the primary examination 
sites.
8.3 Temperature sensation is considered impaired if ≥2 out of 3 contacts per 




























































For standardized assessment of the severity of both neuropathic symptoms and signs, 
various scores may be used, which vary with respect to their individual components66–73 
(Table 5).
Table 5. Scores for assessment of neuropathic symptoms and signs. 
Score NSS66 TSS67 NTSS-668 mTCNS69 NDS66 MNSI-E70 UENS71
Neuropathic symptoms X X X X - - -
Burning X X X X
Tingling/prickling X X X X
Numbness/insensitivity X X X X
Weakness X - - X
Cramps X - - -
Ataxia - - - X
Pain/aching/tightness X X X X
Sharp, shooting, lancinating pain - - X -
Allodynia/hyperalgesia - - X -
Upper limb symptoms - - - X
Neuropathic signs - - - X X X X
Foot inspection/ulcers - - X -
Ankle reflex - X X X
Muscle strength - - - X
Proprioception X - - X
Vibration sensation (tuning fork) X X X X
Pressure sensation (10 g monofilament) - - Xa -
Light touch sensation X - - -
Pain sensation X X - X
Allodynia/hyperesthesia - - - X
Temperature sensation X X - -
Validation of score No No Yes68 Yes69,72 No Yesa 70,72,73 Yes71,72
Threshold for DSPN (points) ≥3* No ≥6 ≥3 ≥3* ≥2.5 ≥3
Footnotes/abbreviations: X included in score; - not included in score; NSS: Neuropathy 
Symptom Score; TSS: Total Symptom Score; NTSS-6: Neuropathy Total Symptom Score-6; 
NDS: Neuropathy Disability Score; MNSI-E: Michigan Neuropathy Screening Instrument 
Examination part; mTCNS: Modified Toronto Clinical Neuropathy Score; UENS: Utah Early 
Neuropathy Scale; a validated before monofilament test was included in the score; DSPN: 
diabetic sensorimotor polyneuropathy; * minimum acceptable criteria for diagnosis of DSPN 
were defined as NDS≥6 with or without NSS≥3 or NDS≥3 with NSS≥6.
To facilitate the physician’s decisions, algorithms for screening, diagnosis, and 
management of DSPN in clinical practice were developed (Figures 1-3). The corresponding 
levels of agreement are summarized in Table 6.
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Table 6: Levels of agreement for algorithms for screening, diagnosis and management of 
diabetic sensorimotor polyneuropathy (DSPN) in clinical practice as depicted in Figures 1-3 
Figure 1
Screening and diagnosing DSPN in 
clinical practice 
Figure 2
Choice of treatment options for 
DSPN in clinical practice
Figure 3
Analgesic pharmacotherapy and 
non-pharmacological treatment 








































Overall agreement 93%, 
Consensus endorsed
Overall agreement 86%, 
Consensus endorsed
Overall agreement 93%, 
Consensus endorsed
The consensus recommendation for an algorithm to screen for and diagnose DSPN in 
clinical practice is shown in Fig. 1.
Treatment of DSPN and neuropathic pain
There are three major principles in the management of DSPN: 1) optimal diabetes 
treatment including lifestyle modification, intensive glucose control and multifactorial 
cardiovascular risk intervention, 2) pathogenetically oriented pharmacotherapy, and 3) 
symptomatic pain relief.
Causal treatment
In the large Look AHEAD study including overweight or obese participants with type 
2 diabetes, a less prominent increase in neuropathic symptoms, but not neuropathic signs was 
observed in the group receiving an intensive lifestyle intervention program focusing on 






































control group that was assigned to a diabetes support and education program74. The 
DCCT/EDIC study demonstrated that intensive insulin therapy aimed at achieving near-
normal glycemia is essential to prevent, albeit not completely, or delay progression of DSPN 
in patients with type 1 diabetes. However, there is no convincing evidence in type 2 diabetes 
patients to suggest that intensive diabetes therapy has a favorable effect on the development 
or progression of DSPN. The Steno 2 Study assessed the effect of multifactorial 
cardiovascular risk intervention on diabetic complications, but could not demonstrate a 
favorable effect on DSPN75–77 . Nonetheless, there is general agreement that glucose control 
should be optimized to prevent or slow the progression of DSPN in people both with type 1 
and type 2 diabetes2.
Pathogenetically oriented pharmacotherapy
The pathogenesis of diabetic neuropathy is multifactorial78. Hyperglycemia and 
dyslipidemia result in a substrate excess in mitochondria leading to mitochondrial dysfunction 
and overproduction of reactive oxygen species (ROS) and reactive carbonyls. ROS and 
carbonyl stress-mediated nuclear DNA damage activates poly(ADP-ribose) polymerase-1 
(PARP1). Upstream inhibition of key glycolytic enzymes by oxidative stress activates major 
pathways implicated in the development of diabetic neuropathy: polyol pathway, hexosamine 
pathway, protein kinase C (PKC) activity, and advanced glycation end products (AGEs) 
pathway79. Based on these pathogenetic mechanisms, pharmacotherapies have been 
introduced to favorably influence the underlying neuropathic process rather than for 
symptomatic pain treatment80.
For clinical use, the antioxidant -lipoic acid and the thiamine derivative (prodrug) 
and AGE inhibitor benfotiamine are licensed as drugs and approved for treatment of DSPN in 
several countries worldwide81,82. Actovegin, a deproteinized ultrafiltrate of calf blood and 
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poly(ADP-ribose) polymerase (PARP) inhibitor, is authorized mainly in Russia and eastern 
European countries, while the aldose reductase inhibitor epalrestat is marketed only in Japan 
and India83,84. Several meta-analyses demonstrated that infusions of -lipoic acid (600 mg 
i.v./day) ameliorated neuropathic symptoms and deficits (signs, impairments) after 3 weeks. 
Moreover, treatment for 5 weeks and 6 months using -lipoic acid 600 mg QD and BID 
orally, respectively, reduced the main symptoms of DSPN including pain, paresthesias, and 
numbness82,85–94. In the NATHAN 1 trial, neuropathic deficits were improved after 4 years in 
patients with mild to moderate largely asymptomatic DSPN86. By contrast, vitamin E (mixed 
tocotrienols) as another antioxidant did not reduce neuropathic symptoms after 1 year of 
treatment95. The BENDIP study showed that neuropathic symptoms, with NSS as the primary 
endpoint, were improved after 6 weeks of treatment using a benfotiamine dose of 300 mg BID 
but not 300 mg QD96. Additional long-term RCTs could further strengthen the rationale for 
use in clinical practice. Both -lipoic acid and benfotiamine, have favorable safety profiles 
even during long-term treatment. An overview on the usual dosages, most frequent adverse 
events, and scientific evidence is given in Table 787–94,96–107.
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Table 7. Dosages, adverse events and scientific evidence of pharmacotherapies used in the 
management of DSPN in clinical practice 












Pathogenetically oriented treatment of symptomatic DSPN
-lipoic acid° Antioxidant 600 (oral)
or 10-15 i.v.
600 (oral) 1 shot 600 (i.v. and 
oral)
None Meta-analyses87–94
Benfotiamine° Vitamin B1 
derivative




Symptomatic treatment of painful DSPN
Gabapentin° 2δ Calcium 
channel ligand
300-600 1200-3000 3-4 divided 
dosages









Pregabalin#$ 2δ Calcium 
channel ligand
75-150 150-450 2-3 divided 
dosages 








Duloxetine#$ SNRI 30 60 1 shot 120 Somnolence, 







SNRI 37.5 150–225 2-3 divided 
dosages 
375 Insomnia, dizziness, 
sedation, headache, 





Amitriptyline° TCA 10-25 25-100 2 doses 150 (doses 
























50-100 100-200 Spread over 
the day
























50-100 up to 200 Spread over 
the day





















Footnotes/Abbreviations: ° National authorizations for treatment of DSPN; # Authorization 
by the European Medicine Agency (EMA) for the treatment of (neuropathic) pain or painful 
DSPN; $ Authorization by the U.S. Food and Drug Administration (FDA) for the treatment of 
(neuropathic) pain or painful DSPN; * based on Summary of Product Characteristics (SPCs) 
of originator products according to EMA or the Federal Institute for Drugs and Medical 
Devices in Germany (BfArM); ** Frequency of events ≥1/10 according to SPCs of originator 
products by EMA or BfArM; §mixed results; DSPN: diabetic sensorimotor polyneuropathy; 
i.v.: intravenous; n.a.: not applicable; RCTs: randomized controlled trials. TRPV1: Transient 
receptor potential vanilloid-1; SRI: Serontinin reuptake inhibitors; SNRI: serotonin-
norepinephrine reuptake inhibitors; TCA: tricyclic antidepressants
The consensus recommendations for pathogenetically oriented pharmacotherapy of 
DSPN are summarized in Table 8.
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Table 8: Consensus recommendations for pharmacotherapy of DSPN.





9.1 Alpha-lipoic acid and benfotiamine have been approved for the treatment of 
symptomatic DSPN in several countries but not by the FDA and EMA.
9.2 Pathogenetically oriented treatment with alpha-lipoic acid and benfotiamine may 
be used for the treatment of symptomatic DSPN, where available.
9.3 Pathogenetically oriented treatment with alpha-lipoic acid may also be used for the 
treatment of neuropathic deficits, where available86.










Overall agreement 93%, Consensus endorsed
Gabapentinoids
10. 1 Gabapentin or pregabalin are considered 1st line analgesic treatments for painful 
DSPN.










Overall agreement 100%, Consensus endorsed
Antidepressants
11.1 Duloxetine and amitriptyline are considered 1st line analgesic treatments for 
painful DSPN.
11.2 If duloxetine is not tolerated, venlafaxine could be an option.











Overall agreement 93%, Consensus endorsed
Tramadol 
12.1 Tramadol is considered 2nd line analgesic treatment for painful DSPN.
12.2 If tramadol is not available or effective, preferably oxycodone or tapentadol could 
be an option, other strong opioids might be used depending on the experience of the 
physician. Referral to specialists or centers with expertise in strong opioid use is 
recommended.
Strong opioids
12.3 Strong opioids are considered 3rd line analgesic treatments for painful DSPN.
12.4 Risk for abuse, misuse, dependence and tolerance should be assessed at the start 
of treatment and regularly during follow-up.










Overall agreement 87%, Consensus endorsed
Topical analgesics
13.1 Topical analgesics such as capsaicin cream (0.025-0.075%) or patch (8%) may be 
used in the treatment of painful DSPN in clinical practice.
13.2 Capsaicin (8% patch) is considered 3rd line analgesic treatment for painful DSPN, 










Overall agreement 93%, Consensus endorsed
Footnotes/Abbreviations: EMA: European Medicine Agency; FDA: U.S. Food and Drug 






























































Symptomatic treatment of painful DSPN
The following general considerations in the pharmacotherapy of neuropathic pain 
require attention108,109:
• The appropriate and effective drug has to be tried and identified in each patient by 
carefully titrating the dose based on efficacy and side effects.
• Lack of efficacy should be judged only after 2-4 weeks of treatment using an adequate 
dose.
• A reduction of pain of 30-49% may be considered a “clinically relevant” response. A 
reduction of ≥50% may be considered a “robust” pain relief associated with important 
beneficial effects on sleep interference, fatigue, and depression as well as quality of life, 
function, and work.
• Because the evidence from clinical trials suggests only a maximum response of 50% for 
any monotherapy, analgesic combinations may be useful.
• Potential drug interactions have to be considered given the frequent use of polypharmacy 
in diabetic patients. 
The most recent guidelines for pharmacotherapy of painful DSPN specifically and 
neuropathic pain in general are summarized in Table 1. These recommendations vary 
considerably depending on their trial selection criteria and methodology used. In summary, 
the most frequently recommended drug classes for the treatment of painful DSPN include α2δ 
subunit ligands (pregabalin, gabapentin), serotonin and norepinephrine reuptake inhibitors 
(preferably duloxetine), and tricyclic antidepressants (preferably amitriptyline). While some 
of these guidelines claim a high strength of evidence (SOE) for their recommendations of 1st 
choice agents, a recent systematic review concluded that the SOE for reducing pain associated 
with DSPN is moderate for the serotonin noradrenaline reuptake inhibitors (SNRI) duloxetine 
and venlafaxine and is low for tricyclic antidepressants (TCA) and anticonvulsants 
pregabalin, and oxcarbazepine, whereas gabapentin was not recommended at all.101 For 
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example, 8 out of 15 trials that evaluated the efficacy of pregabalin in painful DSPN failed to 
demonstrate significantly more pain reduction with this drug than with placebo, and 
gabapentin was rated as ineffective101. Likewise, in the Comparative Effectiveness Review 
Number 187 prepared for the Agency for Healthcare Research and Quality (U.S.), the only 
class with moderate strength of evidence for reducing pain associated with DSPN was SNRI, 
while pregabalin and oxcarbazepine, atypical opioids, botulinum toxin, and α-lipoic acid were 
more effective than placebo albeit with low SOE93. Since the strength of evidence derived 
from systematic reviews, on which recommendations for pharmacotherapy of painful DSPN 
are based, is highly variable, efforts should be made toward harmonizing these guidelines to 
prevent the treating physician from making wrong decisions.
Gabapentinoids
Pregabalin is the most frequently studied drug in DSPN. In contrast to gabapentin, it shows a 
linear, dose-dependent absorption in the therapeutic dose range and a more rapid onset2. 
Pregabalin and gabapentin may be used in patients with impaired liver and autonomic nervous 
system function and at markedly reduced doses also in patients with renal dysfunction. 
However, their use is associated with weight gain, oedema, and central nervous adverse 
effects such as somnolence or dizziness (Table 7). They should be used with caution in 
patients taking pioglitazone or those with congestive heart failure and NYHA class III or IV. 
A pooled trial analysis showed that the risk for adverse events was associated with increasing 
pregabalin dose but not older age110. An earlier meta-analysis reported that treatment with 
pregabalin improved neuropathic pain in patients with painful DSPN in a dose-dependent 
manner, with 600 mg/day being more effective than 300 mg/day111. A recent Cochrane review 
concluded that pregabalin shows efficacy in painful DSPN, whereby some people will derive 
substantial benefit with pregabalin, more will have moderate benefit, and many will have no 
benefit or will discontinue treatment103. Furthermore, the aforementioned recent systematic 
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reviews suggested a low strength of evidence for pregabalin93,101. Another Cochrane review 
concluded that gabapentin at doses of 1800-3600 mg daily (1200 mg to 3600 mg gabapentin 
encarbil) can provide good levels of pain relief to some people with painful DSPN. Around 3 
to 4 out of 10 participants with neuropathic pain achieved ≥50% pain relief with gabapentin, 
compared with 1 to 2 out of 10 for placebo. Over half of those treated with gabapentin will 
not have worthwhile pain relief but may experience adverse events99. In the COMBO-DN 
study, pregabalin (300 mg/day) was less effective in painful DSPN than duloxetine (60 
mg/day), although there was no difference at maximum doses of each (pregabalin 600 mg/day 
and duloxetine 120 mg/day).112 The consensus recommendations on the use of gabapentinoids 
are summarized in Table 8. A recent meta-analysis suggested that misuse and abuse of 
gabapentinoids represents a growing problem in the U.S. and in Europe. Hence, cautious use 
in populations at risk and monitoring for signs of misuse or abuse is needed113.
Tricyclic antidepressants (TCA)
The putative mechanisms of pain relief by antidepressants include the inhibition of 
norepinephrine and/or serotonin reuptake at synapses of central descending pain control 
systems and the antagonism of N-Methyl-D-Aspartate receptor. Among TCA, amitriptyline is 
more widely used in painful DSPN than nortriptyline, imipramine, and desipramine. The most 
frequent adverse events of TCA include fatigue, dry mouth, and weight gain. TCA are 
contraindicated in patients with orthostatic hypotension, prostate hyperplasia, closed-angle 
glaucoma, unstable angina, recent (<6 months) myocardial infarction, heart failure, history of 
ventricular arrhythmias, significant conduction system disease, and long QT syndrome. 
Anticholinergic side effects may aggravate cardiovascular and colonic autonomic neuropathy 
(Table 7) and doses >100 mg should be avoided in elderly. Table 8 summarizes the consensus 
recommendations for the treatment with amitriptyline.
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Serotonin noradrenaline reuptake inhibitors (SNRI)
Seven RCTs confirmed that duloxetine reduces neuropathic pain effectively and to a 
clinically meaningful degree in patients with painful DSPN. Systematic reviews consistently 
reported efficacy with moderate strength of evidence93,101,106. Pain severity but not variables 
related to diabetes or neuropathy has been identified to predict the effect size of duloxetine in 
painful DSPN114. Benefits include a favorable effect on concomitant depression, a frequent 
comorbidity in patients with painful DSPN115, and unlike TCAs and gabapentinoids, the drug 
does not cause weight gain. However, duloxetine has to be avoided in patients with significant 
renal or hepatic disease, and most frequent adverse events include somnolence, headache, and 
nausea (Table 7). Blood pressure should be monitored during the treatment and the risk of 
bleeding should be considered in patients under anticoagulants. When discontinuing treatment 
with duloxetine, the potential of withdrawal symptoms ranging from 6 to 55% in RCTs and 
open trials, should be considered116. Consensus recommendations for duloxetine are given in 
Table 8.
Opioids
The best studied opioids in painful DSPN are tramadol (weak opioid agonist and SNRI), 
oxycodone (µ opioid agonist), and tapentadol (µ opioid agonist and SNRI). However, 
Cochrane reviews concluded that only limited evidence is available from small studies using 
oxycodone and tramadol in painful DSPN 117,105. Frequent adverse events include 
somnolence, headache, and nausea (Table 7). Since tramadol and tapentadol have serotonin 
reuptake inhibitor properties, these agents should not be combined with serotonergic drugs 
(caveat: serotonin syndrome). In a recent meta-analysis of RCTs of patients with chronic 
noncancer pain, evidence from high-quality studies showed that opioid use was associated 
with statistically significant but small improvements in pain and physical functioning, and 
increased risk of vomiting compared with placebo.118 Comparisons of opioids with nonopioid 
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alternatives suggested that the benefit for pain and functioning may be similar, although the 
evidence was from studies of only low to moderate quality. Opioids were associated with less 
pain relief during longer trials possibly due to opioid tolerance or opioid induced 
hyperalgesia118. The European clinical practice recommendations on opioids for chronic 
noncancer pain recently suggested to first optimize established non-pharmacological 
treatments and non-opioid analgesics and only thereafter to consider opioid treatment if 
established non-pharmacological treatments or nonopioid analgesics are not effective and/or 
not tolerated and/or contraindicated119. In a retrospective population-based cohort study, 
adverse outcomes were more common among patients with polyneuropathy (68% with 
diabetes) receiving long-term (≥90 days) compared with short-term (<90 days) opioid 
therapy, including depression, impaired functional status, opioid dependence, and opioid 
overdose,120 supporting a limitation of treatment duration for opioids to 3 months whenever 
possible. Opioid dependence (addiction or opioid use disorders) describes a maladaptive 
pattern of substance use with behavioural changes constituting one of the most important 
substance use disorders contributing to substantial morbidity and premature mortality.121 
Hence, prevention of harm due to opioids is an important aspect in clinical practice.121 
Consensus recommendations for the use of opioids are given in Table 8.
Topical analgesics
Topical analgesic therapy may be an alternative option to systemic pharmacotherapy, as 
it is associated with lower rates of side effects and has lower potential for drug interactions. 
Capsaicin, a highly selective agonist of transient receptor potential vanilloid-1 (TRPV1), is 
authorized as an 8% dermal patch for the treatment of peripheral neuropathic pain,122 yet 
should not be used in active skin lesions. In one RCT in patients with painful DSPN, 
capsaicin 8% patch applied for 30 min provided modest relief of pain within 3 months107. 
Application requires trained staff and suitable infrastructure and can be repeated every 2-3 
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months where appropriate (Table 7). A Cochrane Review focusing on topical low-dose 
(0.025% to 0.075%) capsaicin treatment summarized that no conclusions could be drawn due 
to insufficient data123. Table 8 lists the consensus recommendations for topical analgesic 
treatment with capsaicin.
Lidocaine 5% patch is being used in patients with neuropathic pain due to postherpetic 
neuralgia124, but has not been adequately studied in those with painful DSPN.
Other interventions
Simple analgesics (e.g. ibuprofen, diclofenac, paracetamol) do not constitute appropriate 
treatment options for painful DSPN. As concerns cannabis-based medicine, the potential 
benefits in chronic neuropathic pain might be outweighed by their potential harms125, and 
treatment of neuropathic pain due to DSPN with the cannabinoid compound Sativex was not 
effective126,127. 
People with diabetes are at risk of developing vitamin D, vitamin B12 and/or other 
vitamin B deficiencies (see Table 3, differential diagnosis)65,128–130. In patients with deficient 
status, these vitamins should be supplemented. Vitamin B12 supplementation in deficient 
patients with DSPN has been shown to be effective in reducing neurophysiological 
parameters, pain intensity, and sudomotor function131. Excessive vitamin B6 ingestion may 
cause neurotoxicity132–135. Magnesium as a natural calcium antagonist, is known to block the 
N-methyl-D-aspartate (NMDA) receptor excitability and is of importance for nerve impulse 
conduction136. Evidence suggests that diabetes and DSPN are associated with reduced 
magnesium levels137–139. Symptoms such as paraesthesias and numbness have been described 
in magnesium deficiency140,141. Therefore, magnesium substitution may be relevant in 




Overall, only 50% of subjects with painful DSPN respond to analgesic 
monotherapy31,109.  Therefore, combination pharmacotherapy is required in patients who have 
only partial response or in whom the drug cannot be further titrated due to intolerable side 
effects. There is agreement that patients should be offered the available therapies in a stepwise 
fashion. Effective pain treatment considers a favorable balance between pain relief and side 
effects without implying a maximum effect. Synergistic interactions of drug combinations 
might provide superior analgesia and fewer side-effects than monotherapy by targeting 
multiple mechanisms31,109.  Although the evidence suggesting that combination therapy is 
superior to monotherapy is limited,142–144 patients who cannot tolerate higher doses or do not 
respond with sufficient pain relief may benefit from combination pharmacotherapy, in 
particular from combinations of gabapentinoids and antidepressants145–147. In the COMBO-
DN study, titration to high-dose monotherapy with either pregabalin (300 mg BID) or 
duloxetine (60 mg BID) in non-responders with painful DSPN was equally effective as the 
combination of both (300 mg/day and 60 mg/day) over 8 weeks112. The OPTION-DM trial, 
that has just concluded has examined if two drug combination treatments (duloxetine, 
pregabalin and amitriptyline) provide additional analgesia than monotherapy (Selvarajah et al. 
trials). The advantages and disadvantages of the various drugs and drug classes used for 
treatment of painful DSPN under consideration of the various comorbidities and 
complications associated with diabetes as well as potential drug interactions are summarized 
in Table 9148.
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Table 9. Differential therapy of DSPN taking into account comorbidities and interactions 
(modified from Ziegler et al.148)







α-lipoic acid / 
benfotiamine
Depression +a ±a + ± ± ±
Generalized 
anxiety disorder + + + + ± ±
Insomnia + + + + + ±
Autonomic 
neuropathy ± ± ↓
b ↓c ± +d
Obesity ± ↓ ↓ ± ± ±
Coronary heart 
disease ± ± ↓ ± ± ±
Fasting blood 
sugar level (↓) ± (↓) ± ± (+)
d











Interactions ↓ ± ↓ ± ± ±
Pathogenetically 
oriented therapy No No No No No Yes
Footnotes/abbreviations: + favorable effects, (+) limited evidence for favorable effects; ↓ 
unfavorable effects, (↓) limited evidence for unfavorable effects; ± no relevant effects; a 
Additional anxiolytic effect in generalized anxiety disorder (GAD); b Caution in micturition 
disorders or cardiovascular autonomic neuropathy due to anticholinergic side effects; c 
Caution due to slowing of gastrointestinal transit in gastrointestinal neuropathy; d Applies to 
α-lipoic acid only; e Depending on the single agent; DSPN: diabetic sensorimotor 
polyneuropathy.
Non-pharmacological treatment
Because there is no entirely satisfactory pharmacotherapy of painful DSPN, non-
pharmacological treatment options such as psychological support, physical measures, 
transcutaneous electrical nerve or muscle stimulation, and acupuncture should always be 
considered despite the relatively low level of evidence91. In patients with refractory painful 
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DSPN, spinal cord stimulation leads to pronounced pain relief and improved quality of life149–
151. This invasive treatment option should be reserved for patients who do not respond to 
analgesic combination pharmacotherapy (Table 10).
Table 10: Consensus recommendations for combination pharmacotherapy and non-
pharmacological treatment in DSPN.
Footnotes/abbreviations: DSPN: diabetic sensorimotor polyneuropathy; TENS: 
transcutaneous electrical nerve stimulation; FREMS: frequency-modulated electromagnetic 
neural stimulation.
Figure 2 shows the consensus recommendation of the algorithm for the choice of 
treatment options for DSPN in clinical practice.







14.1 In clinical practice different treatment approaches may be 
combined.
14.2 Possible combinations include a mix of different analgesic 
treatments (mainly antidepressants + gabapentinoids, or 
combinations with opioids as 3rd choice), analgesics plus 
pathogenetically oriented treatments (mainly antidepressants or 
gabapentinoids + α-lipoic acid or benfotiamine) as well as a mix of 
different pathogenetically oriented treatments (mainly α-lipoic acid + 
benfotiamine).











Overall agreement 87%, Consensus endorsed
Non-pharmacological treatment
15.1 Non-pharmacological treatment options such as psychological 
support, behavioral treatment, acupuncture, physical measures, 
transcutaneous electrical and electromagnetic stimulation (TENS, 
FREMS) may be used.
15.2 Electrical spinal cord stimulation may be indicated in patients 
resistant to pharmacotherapies, but should be done in specialized 
units.
15.3 Evidence supporting the efficacy of non-pharmacological 




































The consensus recommendation of the algorithm for analgesic mono- and 
combination-pharmacotherapy and non-pharmacological treatment options in painful DSPN 
in clinical practice is illustrated in Fig. 3.
Influence of COVID-19 pandemic and lockdown situation
Coronavirus disease 2019 (COVID-19) has brought several challenges in the 
management of people with diabetes. Nationwide studies in England and South Korea show 
that type 1 and type 2 diabetes are independently associated with worse clinical outcomes as 
well as with a significantly increased risk of in-hospital mortality with COVID-19 compared 
to people without diabetes152,153. Conversely, the COVID-19 pandemic interferes with 
diabetes care in several aspects: first, lock-down situations have reduced access to routine 
check-ups, screenings and educational programs; and second, diabetes health care 
professionals have been shifted to the care of COVID-19 patients154. A survey among 1829 
diabetes nurses across Europe confirmed that psychological as well as physical problems, 
including acute hyperglycemia, and foot complications were perceived to have increased “a 
lot” in patients with diabetes154. A recent retrospective review of patients necessitating a 
consultation at the surgery service in 2020 confirmed an amputation risk that was 10.8 times 
higher during the pandemic versus before the pandemic. Additionally, the severity of 
infections and the risk of requiring a major amputation increased155. 
Virtual consultations with diabetes patients via telephone, e-mail or video consultations 
have increased during the COVID-19 pandemic156,154. Telemedicine has been proven effective 
in general diabetes care,157,158 especially in patients with high HbA1c (≥9%) to deliver more 
frequent consultations and in this way achieve greater improvement157. The use of 
telemedicine during the COVID-19 pandemic is in general well-received by the patients159–
161. The majority of patients judged the remote visits as “useful”160 and rated their experience 
as “just as good as” or “better than” their traditional face-to-face experience, yet 35% 
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complained about the fact that a physical examination could not be performed159. Notably, 
patients seemed to be worried more about diabetic foot syndrome than COVID-19160. As the 
implementation of remote monitoring for patients with chronic conditions increases, questions 
about the appropriate usage of this care model arise. It has recently been highlighted that 
clinical studies are urgently needed to identify which patients will benefit and which 
technologies are most useful and effective162,161.
The management of patients with diabetic foot ulcers presents a unique challenge in the 
COVID-19 pandemic era because of the frequent need for “face-to-face” consultations for 
wound care156. Strategies for risk stratification, management of diabetic foot problems and 
prevention of hospital admission have been described156,163,164.   
Although consensus guidelines and recommendations for pain management of patients 
with chronic pain have been released by pain medicine specialists165–167, no data or 
experiences have been published concerning the screening of diabetes patients for DSPN or 
the management of patients with DSPN during the COVID-19 pandemic and lockdown 
situations. In the routine care of diabetes patients it is important to keep in mind the need for 
thorough examination of the feet156. Patients with asymptomatic DSPN might not be 
diagnosed with the condition and those who have “lost the gift of pain” are less likely to seek 
help when needed156. The consensus recommendations for COVID-19 pandemic and 
lockdown situation are summarized in Table 11.
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Table 11: Consensus recommendations for the examination and management of diabetic 
sensorimotor polyneuropathy (DSPN) during the COVID-19 pandemic and lockdown 
situation.




16.1. Remote visits are becoming increasingly important, especially during 
the COVID-19 pandemic and lock-down situations.
16.2 Assessment of neuropathic symptoms via patient interview and 
completion of appropriate questionnaires and scores as well as access to 
electronic patient records constitute essential parts of remote visits.
16.3 Treatment of neuropathic symptoms may be initiated and adjusted via 
remote consultations.
16.4 Personal follow-up visits remain indispensable for all patients, 
especially for those at risk of foot ulceration.
16.5 As up to 50% of cases with DSPN may be asymptomatic2, a high 
proportion of patients cannot be captured via remote visits and an 










Overall agreement 100 %, Consensus endorsed
Strengths and limitations
Strengths of the present consensus recommendations include 1) the holistic view on the 
treatment of DSPN, including pathogenetically oriented and symptomatic treatment 
approaches, 2) the use of a structured consensus finding process applying the Delphi 
methodology, 3) detailed recommendations for the screening and diagnosis in clinical 
practice, and 4) recommendations owed to the current topic of COVID-19 pandemic. This 
consensus report has also some limitations. 1) not all relevant topics could be discussed in 
depth and were beyond the scope of the panel discussion such as pharmacoresistant 
neuropathic pain and 2) not all geographical regions were represented by the panel, as for 

















The increasing burden of diabetes and its complications including DSPN constitute important 
public health challenges both at regional and global levels. While progress has been made 
over the last decades in understanding the pathophysiology of DSPN, the condition still 
remains poorly diagnosed and treated. Hence, effective strategies to improve these 
deficiencies need to be pursued. To reduce the burden resulting from DSPN and its sequela, 
adequate consideration and implementation of strategies aimed at early detection and 
prevention of the condition in national diabetes plans is imperative. Since the efficacy of 
available treatments for DSPN is limited, optimizing the therapeutic armamentarium to 
combat DSPN remains an area of substantial unmet medical need. The evidence for 
interventions in DSPN, as derived from systematic reviews on which recommendations are 
based, is often inconclusive. Therefore, therapeutic algorithms need to be harmonized and 
constantly updated to foster suitable and efficacious treatments in everyday routine. Here we 
provide recommendations and algorithms for screening, diagnosis, and treatment of DSPN in 
clinical practice.
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Figure captions
Figure 1. Consensus recommendation of an algorithm for screening and diagnosing DSPN in 
clinical practice.
Footnotes/Abbreviations: * For screening purposes the application of one single test may be 
appropriate. A single abnormal screening test bilaterally suggests the presence of DSPN and 
may require a more extended diagnostic workup; ** minimal criteria for diagnosis of DSPN 
in clinical practice; *** CAVEAT: healthy elderly might show absent reflexes; + Confirmed 
diagnosis of DSPN based on Toronto Consensus criteria5, consider referral to neurologist 
where appropriate; # Usually restricted to rare difficult cases in whom the diagnosis is 
uncertain; 1 The “Douleur Neuropathique en 4 Questions” (DN4-Interview) may be used to 
screen for neuropathic pain characteristics; 2Includes e.g. the Neuropathy Symptom Score 
(NSS), Total Symptom Score (TSS) or Neuropathy Total Symptom Score-6 (NTSS-6); 
3Includes e.g. the Neuropathy Disability Score (NDS), Michigan Neuropathy Screening 
Instrument Examination part (MNSI-E), Modified Toronto Clinical Neuropathy Score 
(mTCNS) or Utah Early Neuropathy Scale (UENS). DSPN: Diabetic Sensorimotor 
Polyneuropathy; eGFR: estimated glomerular filtration rate; NRS: Numeric Rating Scale; 
VAS: Visual Analogue Scale; TSH: Thyroid-stimulating hormone.
Figure 2. Consensus recommendation of an algorithm for the choice of treatment options for 
DSPN in clinical practice.
Footnotes/abbreviations: + If available. Also improves deficits/impairment/signs; *according 
to Pop-Busui et al.2; ** for more details see Figure 3 (algorithm for analgesic combinations); 
CVD: cardiovascular disease; DSPN: diabetic sensorimotor polyneuropathy; eGFR: estimated 
glomerular filtration rate; TSH: thyroid-stimulating hormone; QoL: quality of life.
Figure 3. Consensus recommendation of an algorithm for analgesic pharmacotherapy and 
non-pharmacological treatment options in painful DSPN in clinical practice.
Footnotes/abbreviations: * Pathogenetically oriented treatment approaches may also be 
considered; DSPN: diabetic sensorimotor polyneuropathy; TCA: tricyclic antidepressants; 
SNRI: serotonin-norepinephrine reuptake inhibitors; TENS: transcutaneous electrical nerve 
stimulation; FREMS: frequency-modulated electromagnetic neural stimulation; + for short 
term use only, whenever possible
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